Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can two old drugs together save young livers?

NCT ID NCT06091345

Disease control Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether giving both midodrine (a blood-pressure drug) and albumin (a protein infusion) to children with cirrhosis and fluid buildup (ascites) could prevent serious complications like kidney injury, low sodium, and confusion. Sixty-one children were split into two groups: one got midodrine plus albumin, the other got midodrine alone. The goal was to see if the combo worked better than midodrine alone at reducing these life-threatening problems.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
midodrine and albumin
What this could lead to
If successful, this combination could help prevent serious complications like kidney injury and improve survival in children with advanced liver disease.
What could go wrong
This is a small, single-center trial with only 61 children. The results may not apply to all patients, and the combination may not provide a clear benefit over standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

61 people

The number who actually took part.

Started

Dec 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

12 to 18 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Children (≤ 18 years) 2. Cirrhosis based on histological/ radiological + endoscopic evidence 3. Clinical ascites (≥ grade 2 ascites) 4. Informed consent from parents (Assent \> 12 years) Exclusion Criteria: 1. Arterial hypertension (Mean Arterial Pressure ≥ 95th centile for age) 2. Presence of Portal vein thrombosis 3. Hepatorenal Syndrome 4. Congestive Heart failure 5. Respiratory failure(PF ratio \<200) 6. Septic shock 7. Presence of Hepatocellular Carcinoma 8. Transjugular intrahepatic Porto Systemic Shunt

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decompensated cirrhosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic liver failure cirrhosis of liver

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver cirrhosis

Contacts and locations

Locations

  • Institute of Liver & Biliary Sciences (ILBS)

    New Delhi, National Capital Territory of Delhi, 110 070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.